id |
ndltd-NEU--neu-1728
|
record_format |
oai_dc
|
spelling |
ndltd-NEU--neu-17282021-05-25T05:10:10ZTargeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complexAlthough significant progress has been achieved in cancer therapy, in the last few decades, there still remains much that is incurable. Treatment usually results in temporary effects, such as improvement in the quality of life, not complete remission.http://hdl.handle.net/2047/d20001225
|
collection |
NDLTD
|
sources |
NDLTD
|
description |
Although significant progress has been achieved in cancer therapy, in the last few decades, there still remains much that is incurable. Treatment usually results in temporary effects, such as improvement in the quality of life, not complete remission.
|
title |
Targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex
|
spellingShingle |
Targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex
|
title_short |
Targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex
|
title_full |
Targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex
|
title_fullStr |
Targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex
|
title_full_unstemmed |
Targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex
|
title_sort |
targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex
|
publishDate |
|
url |
http://hdl.handle.net/2047/d20001225
|
_version_ |
1719406059161911296
|